1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6F3F3F41628BFB859852578290059A065
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/product-launch-and-pre-launch-budget-for-us-market-entry?opendocument
18
19opendocument
2018.232.99.123
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Product Launch Resource Allocation

Winning in the U.S. Marketplace: Pre-launch and Launch Investment Benchmarks for New Products

ID: 5122


Features:

5 Info Graphics

23 Data Graphics

200+ Metrics


Pages/Slides: 38


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Winning in the U.S. Marketplace: Pre-launch and Launch Investment Benchmarks for New Products"

STUDY OVERVIEW

When facing a new product launch, biopharmaceutical organizations must balance the dueling goals of containing costs and producing a successful launch. To handle these twin pressures, launch leaders need to know two things: What are adequate overall investment levels and how much should they spend at key points pre-launch and during launch year.

To shed light on these elusive, yet critical, questions, Best Practices, LLC has published a new study on launch spend that delivers benchmarks on investment levels during and prior to launch. The study also includes overall investment benchmarks by different product types - specialty, primary care and projected peak revenue - for launch year and each of the three years prior to launch. Investment benchmarks also are presented for products by market entry position, i.e. upstart product in crowded market.

This timely study will help biopharmaceutical leaders develop competitive launch and pre-launch budgets to ensure successful U.S market entry for new products. The study provides quantitative metrics that will help companies chart effective budget strategies and allocate funds for new brands.

KEY TOPICS

  • Launch investment benchmarks during four budget years leading up to launch
  • Launch investment benchmarks for primary care and specialty segments
  • Investment data by product therapeutic area, projected revenue and market entry position
KEY METRICS
  • Average launch investment for all products, specialty products and primary care products
  • Total U.S. investment in each of the three years prior to launch and during launch year
  • Total launch investment by new product's projected peak revenue (data for launch year and each of the three years prior to launch)
  • Average launch investment for all products, metabolics products and oncology products
SAMPLE KEY FINDING
  • Ramp-up Patterns: There are predictable investment and ramp-up patterns that tend to allocate nearly half of total (aggregated, four-year) spend during the three years prior to the Launch Year and half during the Launch Year. On average, specialty products invested 58% of funds in the first three years and 42% in the Launch Year. This contrasts with the ramp-up for primary care products, where 44% of the total was spent before launch and 56% in the Launch Year.

METHODOLOGY

Twenty-seven executives and managers at 23 leading biopharmaceutical companies participated in this benchmarking research. Directors and Vice Presidents make up more than three-quarters of the benchmark class.

Industries Profiled:
Pharmaceutical; Consumer Products; Medical Device; Diagnostic; Biotech; Health Care


Companies Profiled:
Abbott Laboratories; ProStrakan; Amylin; Astellas; Bausch & Lomb; Baxter Healthcare; Bayer Healthcare; Bristol-Myers Squibb; EMD Serono; Genzyme; GlaxoSmithKline; Inspire Pharmaceuticals; Lundbeck; Merck; Noven Therapeuticals; Novo Nordisk; Onyx Pharmaceuticals; Regeneron; Roche; Sanofi-aventis; Shire; Teva Pharmaceutical Industries Ltd; Xanodyne Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.